Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes?

Antiviral Res. 2006 Sep;71(2-3):260-7. doi: 10.1016/j.antiviral.2006.05.021. Epub 2006 Jun 28.

Abstract

The genome of human immunodeficiency virus type 1 (HIV-1) encodes 15 distinct proteins, three of which provide essential enzymatic functions: a reverse transcriptase (RT), an integrase (IN), and a protease (PR). Since these enzymes are all homodimers, pseudohomodimers or multimers, disruption of protein-protein interactions in these retroviral enzymes may constitute an alternative way to achieve HIV-1 inhibition. A growing number of dimerization inhibitors for these enzymes is being reported. This mini review summarizes some approaches that have been followed for the development of compounds that inhibit those three enzymes by interfering with the dimerization interfaces between the enzyme subunits.

Publication types

  • Review

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Dimerization
  • Drug Design*
  • HIV Integrase / chemistry
  • HIV Integrase / drug effects*
  • HIV Integrase / metabolism
  • HIV Protease / chemistry
  • HIV Protease / drug effects*
  • HIV Protease / metabolism
  • HIV Reverse Transcriptase / antagonists & inhibitors*
  • HIV Reverse Transcriptase / chemistry
  • HIV Reverse Transcriptase / metabolism
  • HIV-1 / drug effects*
  • HIV-1 / enzymology
  • Humans
  • Models, Molecular
  • Reverse Transcriptase Inhibitors / pharmacology

Substances

  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • HIV Integrase
  • HIV Reverse Transcriptase
  • HIV Protease